Table 2.
Change in biomarkers and CMR findings over a follow-up period of 1 year
| Parameter | Group A = with tafamidis (N = 20) |
Group B = without tafamidis (N = 20) |
∆p value | ||||
|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | p value | Baseline | Follow-up | p value | ||
| NYHA | 3 (2.0–3.0) | 2.0 (2.0–3.0) | 0.10 | 2.0 (1.3–2.0) | 3 (1.3–3.0) | 0.007 | 0.005 |
| NT-proBNP (pg/ml) | 2068 (1646–3267) | 2403 (1857–4112) | 0.046 | 1810 (1260–2858) | 2614 (1059–3526) | 0.011 | 0.20 |
| Major CMR findings | |||||||
| LV-EF (%) | 51 (48–58) | 51 (49–57) | 0.75 | 57 (50–61) | 51 (47–56) | 0.003 | 0.041 |
| LV-EDVi (ml/m2) | 91 (76–102) | 88 (78–103) | 0.72 | 81 (77–98) | 85 (76–92) | 0.17 | 0.16 |
| LV mass index (g/m2) | 104 (90–120) | 106 (89–114) | 0.32 | 90 (82–104) | 92 (86–112) | 0.034 | 0.028 |
| Max. LV thickness (mm) | 20 (18–22) | 20 (17–22) | 0.77 | 20 (17–21) | 20 (18–22) | 0.001 | 0.005 |
| RV-EF (%) | 49 (44–52) | 48 (41–52) | 0.06 | 54 (46–61) | 49 (43–54) | 0.010 | 0.72 |
| RV-EDVi (ml/m2) | 91 (75–101) | 102 (79–109) | 0.006 | 80 (73–102) | 85 (74–100) | 0.96 | 0.014 |
| 3D global longitudinal peak strain (%) | – 7.30 (– 7.70 to – 5.00) | – 6.70 (– 7.10 to – 5.60) | 0.58 | – 8.60 (– 9.33 to – 7.45) | – 7.30 (– 9.08 to – 5.08) | 0.009 | 0.46 |
| Apical/(basal + mid) strain ratio (3D), n | 0.83 (0.67–0.90) | 0.88 (0.69–0.96) | 0.18 | 0.81 (0.79–1.11) | 0.89 (0.8–1.07) | 0.001 | 0.005 |
| Global native T1 [950–1050 ms] | 1111 (1094–1125) | 1111 (1088–1131) | 0.25 | 1097 (1077–1131) | 1116 (1095–1126) | 0.038 | 0.025 |
| Basal septal native T1 [950–1050 ms] | 1110 (1101–1127) | 1104 (1093–1121) | 0.29 | 1096 (1049–1128) | 1095 (1078–1123) | 0.30 | 0.15 |
| Global ECV [25–31%] | 57 (51–62) | 54 (48–63) | 0.19 | 56 (48–60) | 57 (49–62) | 0.017 | 0.016 |
| Septal ECV [25–31%] | 64 (52–70) | 63 (54–68) | 0.57 | 57 (48–66) | 60 (51–69) | 0.007 | 0.021 |
All data are given as median (interquartile range), if not mentioned otherwise. Units are mentioned in small brackets (). Normal range of values are mentioned in large brackets []
CMR cardiovascular magnetic resonance, LV left ventricle, RV right ventricle, EF ejection fraction, EDVi enddiastolic volume index, ECV extracellular volume fraction, ∆p significance between the changes among treated and untreated patients in respective parameters
p < 0.05 is considered as significant